🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI
$76.61
+682.53% 1Y
P/E-16.27
52W High$76.98
52W Low$9.70
EPS (TTM)$-4.71

Company Overview

FBRX (FBRX) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.

Recent Developments

  • Trailing 12 Months Year-on-year growth — revenue -99.8%.
  • 5-Year Trend Long-term compounding — revenue CAGR -9.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:-9.77%
1 Year:-99.80%

Stock Price Performance

1 Year:+682.53%
6 Months:+122.83%
3 Months:+180.73%
1 Month:+244.31%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 99% of range
$9.70 $76.98
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)84.69 · Overbought
Price Performance
1M+244.31%
3M+180.73%
6M+122.83%
1Y+682.53%

Auto-generated from price history and fundamentals; not investment advice.

Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -9.8% CAGR over 5 years.
  • RSI at 85 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Ad space

Valuation

Stock P/E
-16.27
Industry PE
-
Forward P/E
-
PEG Ratio
-
Book Value
$-
Price to Book
-
P/S
-
EV/EBITDA
-
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
-9.77%
Profit 5Y
-
Revenue (YoY)
-99.80%
Earnings (YoY)
-

Profitability & Returns

ROCE
-113.91%
ROE
-113.75%
ROA
-83.81%
Profit Margin
-
Op Margin
-
Gross Margin
-
EPS (Latest Qtr)
$-1.24
EPS (TTM)
$-4.71

Balance Sheet & Liquidity

Debt/Equity
-
Quick Ratio
-
Current Ratio
-
Debt
-
Total Assets
$67.22M
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
2.14%
Chg in Prom Hold
-
FII / Inst Holding
75.77%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
-
Total Revenue (TTM)
$36.00K
EBITDA
-
Free Cash Flow
$-51.00M
Operating Cash Flow
$-50.88M
Shares Outstanding
-
Gross Margin
-
Payout Ratio
-
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----10.00K10.00K-9.00K9.00K18.01M-9.00K9.00K9.00K----------------00000
Cost of Revenue ------------------------------------
Gross Profit ------------------------------------
Operating Expenses -------------------------------16.12M11.58M18.38M24.57M22.44M
Operating Income -7.57M-7.62M-8.53M--8.55M-8.65M-9.74M--12.85M-15.33M1.43M--16.87M-629.00K-684.00K--2.03M-34.75M-5.01M-4.74M-5.75M-7.70M-2.51M-3.02M-3.42M-6.86M-9.03M-10.22M-7.80M-12.82M-8.63M-16.12M-11.58M-18.38M-24.57M-22.44M
EBITDA --------------------------------16.11M-11.56M-18.37M-24.55M-22.42M
Interest Expense ------------------------------------
Pretax Income --------------------------------15.66M-11.25M-17.68M-23.75M-21.76M
Tax Provision -------------------------------0---373.00K
Net Income -8.01M-8.04M-9.00M-8.43M-9.07M-9.07M-9.95M-10.84M-12.88M-16.09M-383.00K-19.60M-1.19M-630.00K-690.00K-10.58M-2.05M-34.76M-5.10M-4.80M-5.81M-7.75M-2.57M-3.04M-3.40M-6.75M-8.90M-9.96M-7.42M-12.51M-8.39M-15.66M-11.25M-17.68M-24.79M-22.14M
Diluted EPS ---------------------0.43-0.54-0.17-0.21-0.18-0.32-0.42-6.57-4.03-6.78-4.54-1.37-0.96-0.99--1.24
R&D Expense 6.47M6.53M7.59M-6.62M6.63M7.56M-10.44M12.76M12.26M-12.43M11.97M13.29M-3.14M-------------------

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -49.00K41.00K18.04M36.00K------
Operating Income -22.95M-31.69M-37.63M-45.85M-4.06M-46.28M-21.49M-13.90M-32.49M-36.60M-70.66M
Net Income -23.06M-33.48M-38.93M-48.95M-4.07M-46.49M-21.71M-13.88M-31.48M-35.48M-69.38M
Diluted EPS -------1.55-0.80-24.92-12.17-4.71
R&D Expense 19.17M27.22M29.11M51.08M45.30M------

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --35.35M92.07M103.08M7.66M61.24M43.31M42.00M38.98M61.56M82.78M
Total Equity -70.44M-92.33M-124.42M71.08M-736.00K-4.77M58.98M41.55M38.82M35.31M52.48M60.99M
Cash & Equivalents 4.20M8.15M5.51M35.93M40.81M6.94M58.77M42.04M41.10M37.12M22.24M76.96M
Long Term Debt --10.24M3.62M26.20M-------
Total Liabilities --28.36M20.99M44.94M17.31M----9.08M21.79M
Current Liabilities --14.38M17.33M16.53M1.91M2.26M1.76M3.18M3.67M9.08M20.75M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow --29.54M-31.13M-34.47M-2.77M-18.42M-16.68M-8.19M-28.71M-30.75M-50.88M
Investing Cash Flow -24.57M-27.71M-4.19M-162.00K3.58M--47.00K-35.99M36.23M
Financing Cash Flow -2.33M89.26M43.54M4.86M66.67M-44.00K7.24M24.68M51.86M69.36M
Capital Expenditure -231.00K-525.00K-655.00K-1.97M-162.00K----88.00K-37.00K-116.00K
Free Cash Flow --30.06M-31.79M-36.44M-2.93M----28.79M-30.78M-51.00M

Ratios (Annual)

Figures in %.

Metric Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -----------
Operating Margin % --64,673.5%-91,775.6%-254.2%-11,288.9%------
Net Margin % --68,322.4%-94,948.8%-271.4%-11,302.8%------
ROE % 25.0%26.9%-54.8%6,651.5%85.3%-78.8%-52.2%-35.8%-89.1%-67.6%-113.7%
ROCE % --151.1%-50.3%-53.0%-70.7%-78.5%-51.7%-35.8%-92.0%-69.7%-113.9%

Shareholding Pattern

Insiders
2.14%
Institutions
75.77%
Public Float
77.43%

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for FBRX

Google News Wed, 05 Aug 2026

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger—FBRX, LXFR, SMTI, and MKTX - Morningstar

<a href="https://news.google.com/rss/articles/CBMi8wFBVV95cUxObWVSTU1yMzhkbXptYVV1dTFCd0VEcGgzeHo4eGZWWXdWR3lja1pDNXJ1U05tMEJ4RjdpM0xfN0poWlg3VWp2RFBzNTFaUEsyZV9rMllUazB0U3dsaDRjQzZsLXFOdnV3UVc2bWhnbXUxOW9sYnhXT202OU43dnpoLVpZSXM2eFI4MHRmTU…

Google News ue, 04 Aug 2026

Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? - Stocktwits

<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQX0lqLWlJX0YzYnhVLVFlOHFGS3NaQXhIWERkLTF1dERhTDJTRVRrOXNjazVoTjcwQkQ0aS1Lem5jSHFEdjdycXQxVks3ZGNvTUtqYnRGWFVjLWpiZWszNXdQZnNEU3pHNXQ4RWZfWDVqTk1ZdUx1eTFpWEoyN25UQjU0bVF6YnVSbUVuOG…

Google News Fri, 10 Jul 2026

FBRX Stock Rallies 78% on Positive Early-Stage Vitiligo Study Data - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMilgFBVV95cUxQODlEdDlsZF9aeFNjY3AyNlpSSTMzQXdQeUg2azRvLXZFWE1DZVNIclJ6eVFRbHNld214TzVGR09xYXhpSGxRMTdLblFDZE1aWE10SmZPbnNPVllTZ05hbWdLMVhreHBJdGNiRmhfZUlDel82ZzJNNFpHdTVDRVRXaksxZ05rN0RLcFdaUj…

Google News Mon, 27 Jul 2026

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today - Barchart.com

<a href="https://news.google.com/rss/articles/CBMiuAFBVV95cUxPLVF1SHliRjVhRW1DMWVkd0JHS1JPTVlaMDVVUUY0bTgtalY4UGstdk9RRjJfWG9CbGlqZVYxbjJseEdNS1E2cGFPZk5nbkF2dXA3UDZEODh3SFd0c2hDeGFERUZMNktZZzZpQ2ZUa3FqcFdnd3JXd0U0a2lyWkpjZEhWOGQxcVg1UWtTaj…

Google News ue, 28 Jul 2026

Forte Biosciences (FBRX) Stock Looks Stretched On Book Value Yet Strong On Pipeline Hope - simplywall.st

<a href="https://news.google.com/rss/articles/CBMi5gFBVV95cUxQbVZCbzJJQnZDYVZ4aEZ4dS1BNzdaNjVrWG93U0hQQllCQm5zaE0xUURKVWVsWm5DLU4wOXdIQ1lhbHBlS0tKU0pvbmVCd1N1Unl0MFBDaVFxNE9GZ1ZIOTUyNUtwMWlwRnZtTEE0OTdOYlJ1Q2dVc0U4QTFoZUZZSFVCX0RMLVV1TkVVYV…

Google News Sat, 01 Aug 2026

Price to sales forward of Forte Biosciences, Inc. – NASDAQ:FBRX - TradingView

<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOZy1aejJlZEJRVFRTbnYwTl9NS0I1c2tYQ2p5cC02dUNyeHZtT0Q3SlZDMVpVa2s5Z0JndmVJSFU3Yzl1b1YwOGlsM0RkUnN4aTlJd3ZBUU5jSHIzQmpCWDRWd20wVlBHN21WYVFFRFY0MTlGakN5RVUtdEhPcmU2eW9sa0FCdFJJV25HYz…

FBRX — Frequently Asked Questions

What is the current share price of FBRX?

As of 2026-08-05 17:25 PDT, FBRX trades at $76.61 on NASDAQ/NYSE. Its 52-week range is $9.70 to $76.98.

What is the P/E ratio of FBRX?

FBRX trades at a trailing price-to-earnings (P/E) ratio of -16.27.

What is the return on equity (ROE) of FBRX?

FBRX has a return on equity (ROE) of -113.75%. Its return on capital employed (ROCE) is -113.91%.

Is FBRX a good stock to buy?

This page provides a data-driven analysis of FBRX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks